|
| |
NicOx S.ANicOx is a product-driven biopharmaceutical company dedicated to the development of nitric oxide-donating drugs to meet unmet medical needs.NicOx is targeting the therapeutic areas of inflammation and cardiovascular disease.The Company’s resources are focused on its two lead compounds in late stage development for the treatment of osteoarthritis and Peripheral Arterial Obstructive Disease (PAOD).NicOx aims to build itself into a fully integrated biopharmaceutical company through focused investment in in-house research and development programs and potentially through in-licensing and by making select acquisitions in its core therapeutic domains of inflammation and cardiovascular disease.
| Contact Details: |
| Gaďa II - 2455 Route des DolinesB.P. 313 |
| Sophia Antipolis Cedex |
| |
| 06 906 |
| France |
| Tel: | 33 (0)4 92 38 70 20 |
| Fax: | 33 (0)4 92 38 70 30 |
| Email: | nicox@nicox.com |
| WWW: | www.nicox.com/
|
| |
Press Releases on NicOx S.A:
|
 |
| Xanodyne Announces Appointment of Mr. Vaughn M. Kailian of MPM Capital to the Board of Directors |
12th June, 2009 |
Xanodyne Pharmaceuticals, Inc. |
NEWPORT, Ky., June 12 /PRNewswire/ -- Xanodyne Pharmaceuticals, Inc. is pleased to announce the appointment of Mr. Vaughn M. Kailian to the Company's Board of Directors. Mr. Kailian is currently
|
| ViroPharma Announces Appointment of Frank Baldino, Jr., Ph.D. to Board of Directors |
8th June, 2009 |
ViroPharma Incorporated |
EXTON, Pa., June 8 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced the appointment of Frank Baldino, Jr., Ph.D. to its board of directors.
Dr. Baldino brings several
|
| Financial Results for Full Year 2008: NicOx in a Unique Position to Deliver Significant Shareholder Value |
26th February, 2009 |
NicOx |
SOPHIA ANTIPOLIS, France, February 26 /PRNewswire-FirstCall/ -- NicOx
S.A. (NYSE Euronext Paris: COX) today announced its financial results for
full year 2008 and provided an overview of the
|
| NicOx Announces Results for TPI 1020 in COPD |
23rd December, 2008 |
NicOx |
SOPHIA ANTIPOLIS, France, December 23 /PRNewswire-FirstCall/ -- NicOx
S.A. (NYSE Euronext Paris: COX) today announced the results of a phase 2a
study for TPI 1020, conducted in 62 patients with
|
| NicOx' Naproxcinod Shows Differentiated 24-Hour Blood Pressure Profile After 13 Weeks Treatment |
19th December, 2008 |
NicOx |
SOPHIA ANTIPOLIS, France, December 19 /PRNewswire-FirstCall/ -- NicOx
S.A. (Euronext Paris: COX) today announced positive results from the 112
clinical pharmacology study in 299 patients with
|
 Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 320 times since April 2007, the link to the organisation's website has been followed 46 times Search for more companies in Sophia Antipolis Cedex Search for more companies in This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for NicOx S.A |
